Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 28

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

HER2 positive breast cancer

Recruiting

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Solti Group

Neoplasm

Recruiting

A Study Testing How Pralsetinib Affects Other Medications in Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pralsetinib
  • Sponsor:Rigel Pharmaceuticals Inc.

Chronic lymphocytic leukaemia+1

Recruiting

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673
  • Sponsor:BeOne Medicines AG

Oesophageal adenocarcinoma

Recruiting

Study of zanidatamab with drug combination for patients with HER2 and PD-L1 positive advanced gastroesophageal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Pancreatic carcinoma metastatic+1

Recruiting

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

B-cell type acute leukaemia

Recruiting

A Study to Test the Safety and How AZD4512 Works in Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:AZD4512
  • Sponsor:AstraZeneca AB

Non-Hodgkin's lymphoma

Recruiting

A Study of AZD4512 Alone or With Other Cancer Drugs for People With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD4512
  • Sponsor:AstraZeneca AB

Neoplasm

Recruiting

Testing GSK5764227 combined with standard cancer treatments in patients with advanced solid tumors to evaluate safety and effectiveness

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Oesophageal adenocarcinoma+2

Recruiting

A study to test the safety and effectiveness of ONA-255 in patients with advanced cancer including breast cancer and gastric cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Ona Therapeutics S.L.

Neurofibromatosis+1

Recruiting

A study of mirdametinib for infants and toddlers under 24 months of age with neurofibromatosis type 1 associated plexiform neurofibromas

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Sponsor:Merck Healthcare KGaA

Acute myeloid leukaemia+1

Recruiting

A Study of Gilteritinib to Eliminate Remaining Cancer Cells in Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hellenic Society Of Hematology

Head and neck cancer metastatic

Recruiting

Comparing Two Treatment Lengths of Cetuximab, Avelumab, Cisplatin, and Docetaxel for Patients with Returning Spread Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.